Search Results for "Drug Interactions"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Drug Interactions. Results 671 to 680 of 1090 total matches.
Levomilnacipran (Fetzima): A New SNRI for Depression
The Medical Letter on Drugs and Therapeutics • Dec 23, 2013 (Issue 1432)
The Medical Letter®
On Drugs and Therapeutics
Volume 55 (Issue 1432)
December 23, 2013 ...
The FDA has approved levomilnacipran (lee" voe mil
na' si pran; Fetzima – Forest), a serotonin and norepinephrine
reuptake inhibitor (SNRI), for treatment of
major depressive disorder. Levomilnacipran is the
more active enantiomer of milnacipran (Savella), which
was approved in 2009 for management of fibromyalgia. Fetzima has not been studied in fibromyalgia.
Anoro Ellipta: An Inhaled Umeclidinium/Vilanterol Combination for COPD
The Medical Letter on Drugs and Therapeutics • Apr 14, 2014 (Issue 1440)
; no adequate studies in
women) for use during pregnancy.
DRUG INTERACTIONS — Vilanterol is a CYP3A4
and P ...
The FDA has approved an inhaled fixed-dose
combination of the long-acting anticholinergic
umeclidinium (ue mek" li din' ee um) and the long-acting
beta2-adrenergic agonist (LABA) vilanterol
(Anoro Ellipta – GSK/Theravance) for once-daily
maintenance treatment of chronic obstructive
pulmonary disease (COPD). Anoro Ellipta is the first
product available in the US that combines two long-acting
bronchodilators in a single delivery device.
Recombinant Human Parathyroid Hormone (Natpara)
The Medical Letter on Drugs and Therapeutics • Jun 08, 2015 (Issue 1470)
The Medical Letter®
on Drugs and Therapeutics
Objective Drug Reviews Since 1959
Volume 57 (Issue ...
The FDA has approved a subcutaneously injected
formulation of recombinant human parathyroid
hormone (Natpara – NPS) as an adjunct to calcium
and vitamin D to control hypocalcemia in adults
with hypoparathyroidism. Natpara is an 84-amino
acid single-chain polypeptide identical to native
parathyroid hormone. It is the first parathyroid hormone
formulation to be approved for this indication.
Sonidegib (Odomzo) for Basal Cell Carcinoma
The Medical Letter on Drugs and Therapeutics • Feb 29, 2016 (Issue 1489)
after
their last dose.
DRUG INTERACTIONS — Sonidegib is a substrate of
CYP3A4; the mean AUC ...
The FDA has approved the hedgehog pathway
inhibitor sonidegib (Odomzo – Novartis) for oral
treatment of locally advanced basal cell carcinoma
that cannot be treated with surgery or radiation or
has recurred following such treatment. Vismodegib
(Erivedge), another oral hedgehog pathway inhibitor,
was approved earlier for the same indication and also
for treatment of metastatic basal cell carcinoma.
Escitalopram (Lexapro) for Depression
The Medical Letter on Drugs and Therapeutics • Sep 30, 2002 (Issue 1140)
, it might prove to have fewer drug interactions than some other
SSRIs such as fluoxetine or paroxetine ...
Escitalopram (Lexapro - Forest), the active S-enantiomer of racemic citalopram (Celexa - Forest), a selective serotonin reuptake inhibitor (SSRI), was recently approved by the FDA for treatment of depression. The manufacturer plans to stop promoting Celexa in favor of Lexapro; Celexa will continue to be available for patients already taking it.
Intravenous Ibuprofen (Caldolor)
The Medical Letter on Drugs and Therapeutics • Jan 11, 2010 (Issue 1329)
of reports that it may interfere
with bone healing.
4
DRUG INTERACTIONS — Co-administration of
ibuprofen ...
An intraveneous (IV) formulation of ibuprofen (Caldolor - Cumberland) was recently approved by the FDA for use in adults. It can be administered alone for treatment of mild to moderate pain or as an adjunct to opioid analgesics for moderate to severe pain. It is also approved for reduction of fever.
Sublingual Immunotherapy for Allergic Rhinitis
The Medical Letter on Drugs and Therapeutics • Jun 09, 2014 (Issue 1444)
may be higher.
48 The Medical Letter • Volume 56 • Issue 1444 • June 9, 2014
DRUG INTERACTIONS — All 3 ...
The FDA has approved 3 allergen extracts for sublingual
administration as immunotherapy for allergic rhinitis
confirmed by a positive skin test or in vitro testing for
pollen-specific IgE antibodies: Oralair (Stallergenes
S.A./Greer) and Grastek (Merck) for grass pollen-induced
allergic rhinitis and Ragwitek (Merck) for short
ragweed pollen-induced allergic rhinitis.
Margetuximab (Margenza) for HER2-Positive Breast Cancer (online only)
The Medical Letter on Drugs and Therapeutics • Nov 28, 2022 (Issue 1664)
adjustments that should be made if adverse
effects occur.
DRUG INTERACTIONS — Patients who receive ...
The FDA has approved margetuximab-cmkb
(Margenza – MacroGenics), a HER2/neu receptor antagonist,
for use in combination with chemotherapy
for treatment of metastatic human epidermal growth
factor receptor 2 (HER2)-positive breast cancer in
adults who received ≥2 prior anti-HER2 regimens, at
least one of which was for metastatic disease.
Droxidopa (Northera) for Neurogenic Orthostatic Hypotension
The Medical Letter on Drugs and Therapeutics • Jun 22, 2015 (Issue 1471)
studies in women) for use during pregnancy.
DRUG INTERACTIONS — Concurrent administration
of droxidopa ...
The FDA has approved droxidopa (Northera –
Lundbeck) for oral treatment of adults with symptomatic
neurogenic orthostatic hypotension (NOH) caused
by primary autonomic failure (Parkinson's disease,
multiple system atrophy, or pure autonomic failure),
dopamine beta-hydroxylase deficiency, or nondiabetic
autonomic neuropathy. This is the first approval for
droxidopa in the US. It has been available in Japan for
use in NOH since 1989.
Erdafitinib (Balversa) for Urothelial Carcinoma (online only)
The Medical Letter on Drugs and Therapeutics • May 13, 2024 (Issue 1702)
thereafter.
DRUG INTERACTIONS — Erdafitinib is metabolized
primarily by CYP2C9 and CYP3A4 ...
Erdafitinib (Balversa – Janssen), an oral kinase
inhibitor, has received full approval from the FDA
for treatment of locally advanced or metastatic
urothelial carcinoma in adults with susceptible
FGFR3 (fibroblast growth factor receptor) genetic
alterations who had disease progression on or after
at least one prior line of systemic therapy. It is not
recommended for use in patients who are eligible
for but have not received prior PD-1 (programmed
death receptor-1) or PD-L1 (programmed death-ligand
1) inhibitor therapy. Erdafitinib is the first
oral FGFR kinase inhibitor to be...
Med Lett Drugs Ther. 2024 May 13;66(1702):e83-4 doi:10.58347/tml.2024.1702g | Show Introduction Hide Introduction